1Pass SE,Dusing ML.Current and emerging therapy for primary pulmonary hypertension[J].Ann Pharmacother,2002,36(9):1414-1423.
2Rubin LJ.Pulmonary hypertension[A].In:Murray JF,Nadel JA,eds.Textbook of respiratory medicine[M].3rd ed.Philadephia:Saunders,2000.1524-1552.
3Fernandez A,Guerra MF,Camino E,et al.New etiopathogenic,diagnostic and therapeutic aspects in primary pulmonary hypertension[J].An Med Interna,1995,12(6):294-298.
5Nagaya N.Drug therapy of primary pulmonary hypertension[J].Am J Cardiovasc Drugs,2004,4(2):75-85.
6Barst RJ.Recent advances in the treatment of pediatric pulmonary artery hypertension[J].Pediatr Clin North Am,1999,46(2):331-345.
7Chaouat A,Weitzenblum E.Therapeutic management of primary pulmonary hypertension[J].Presse Med,2002,31(7):320-328.
8Klings ES,Farber HW.Current management of primary pulmonary hypertension[J].Drugs,2001,61(13):1945-1956.
9Wanstall JC,Jeffery TK.Recognition and management of pulmonary hypertension[J].Drugs,1998,56(6):989-1007.
10McLaughlin,Shillington A,Rich S.Survival in primary pulmonary hypertension:the impact of epoprostenol therapy[J].Circulation,2002,106(12):1477-1482.
同被引文献20
1Steen VD, Lucas M, Fertig N, et al. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody[J]. J Rheumatol, 2007,34(11) : 2230-2235.
2Jinnin M, Ihn H, Asano Y, et al. Sclerosing panniculitis is associated with pulmonary hypertension in systemic sclerosis [J]. Br J Dermatol,2005,153(3) :579-583.
3Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence- based clinical practice guidelines [ J ]. Chest, 2007, 131 (6) : 1917-1928.
4Scorza R,Caronni M, Mascagni B, et al. Effects of longterm cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study [J]. Clin Exp Rheumatol,2001,19(5) :503- 508.
5Keogh AM,Jabbour A,Weintraub R, et al. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension [J]. J Heart Lung Transplant, 2007,26 (11) : 1079-1083.
6Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of longterm subcutaneous treprostinil sodium therapy in pulmonary hypertension[J]. Chest,2006,129(6) :1636-1643.
7Miwa K, Matsubara T, Uno Y, et al. Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome[J]. Int Heart J, 2007,48 (3) : 417-422.
8Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension[J]. N Engl J Med, 2002,346 (12) :896-903.
9Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era[J]. Heart, 2006,92 (7) : 926-932.
10Naeije R,Huez S. Expert opinion on available options treating pulmonary arterial hypertension [ J ]. Expert Opin Pharmacother, 2007,8 (14) : 2247-2265.
